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INFLAMMATION AND ANGIOGENESIS 
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Boston, Mass 
The concept of ischemia as the primary stimulus 
of angiogenesis has been recently challenged on the 
basis of a number experimental observations. Thus, 
chronic reduction of myocardial ischemia with ]3- 
blockers has no effect on the development ofcollat- 
eral circulation in chronically ischemic pig, while 
many patients with advanced coronary demonstrate 
extensive neovascularization around the sites of epi- 
cardial coronary artery occlusions. At the same time, 
either direct or indirect measures of myocardial per- 
fusion fail to document tissue ischemia t these sites. 
Other stimuli, such as shear stress and the presence 
of local inflammatory esponse, may be key factors 
involved in control of vessel growth in these settings. 
The presence ofa local "inflammatory" response 
is emerging as a particularly appealing possibility. 
Several experimental observations point to this 
mechanism. Thus, expression ofmonocyte chemoat- 
tractant protein-i (MCP-1) is induced in the 
endothelium ofsmall venules immediately following 
reperfusion, and a local infusion of MCP-1 protein 
into an ischcmic hindlimb resulted in enhanced col- 
lateral growth. 1-3 Furthermore, the presence of 
blood-derived monocytes early after an acute MI 
was associated with enhanced expression of heparan 
sulfate-carrying core proteins 4 that are involved in 
regulation of endothelial cell growthS; in contrast 
the absence of blood-derived monocytes i  associat- 
ed with decreased neovascularization. 
The ability of macrophages to induce angiogen- 
esis is hardly surprising iven the wide variety of 
cytoldnes these c lls are able to secrete, including 
VEGF, FGFs, TNFa, IL-6, and IL-8, among others. 
Studies in a rat acute infarct model suggest that infil- 
trating macrophages and not myocytes or endothe- 
lial cells are the predominant source ofVEGF, 6 and 
unlike other tissues, 7 essentially all cardiac 
macrophages are of blood-derived (monocyte) ori- 
gin.4, 8 VEGF acts as a chemoattractant for 
macrophages 9 and increases their adhesion to 
endothelial cells and the extracellular matrix pro- 
teins. Thus, a local administration (or production) of 
VEGF may lead to increased monocyte-macrophage 
influx followed by release of a number of cytoldnes 
including VEGF and bFGF, thus amplifying the 
original signal. In addition to the cytoldne release, 
macrophages may also be an important source of 
NO generation that in turn can modulate growth 
factor signaling. In that regard, release ofmonocyte- 
derived TNF-a and interleukins will further con- 
tribute to generation of NO by stimulating eNOS in 
endothelial cells. These mechanisms may lie at the 
heart ofVEGF-mediated inductien of angiogenesis. 
In addition to these well-described proteins, 
macrophages also secrete a cathelin-related proline- 
arginine rich peptide, PR39, that was originally iso- 
lated on the basis of antimicrobial activity from the 
pig intestine. 1°The peptide is present in the wound 
fluid 11 as well as along the border of acute myocar- 
dial infarction, 4 and its appearance correlates with 
significant changes in heparan sulfate matrix.4,11 The 
peptide is able to rapidly cross cell membranes and 
has been reported to bind to SH3 domains of 
p47phox 12 and pl30Cas. I3 Recent studies from our 
laboratory have demonstrated that the peptide is 
capable of inducing profound angiogenic response 
by inhibiting proteasomc-dependent gradation of
hypoxia-inducible factor (HIF)-la. This in turn 
leads to a significant increase in expression of a num- 
ber of angiogenesis-related g nes including VEGF 
and VEGF receptors ilk-1 and fit-1 as well as other 
proteins. 14 The implications of these data will be 
discussed. 
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THE FLIP SIDE--VASCULAR APPLICATIONS 
FOR ANGIOGENESIS INHIBITORS 
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Boston, Mass 
There are a number of emerging applications for 
modulators of angiogenesis that impact cardiovascu- 
lar medicine. Concepts learned from our under- 
standing of angiogenesis, vasculogenesis, and the 
assembly of larger arteries may provide new insights 
about cardiovascular disease states that manifest vas- 
cular or myocardial remodeling, intimal hyperplasia, 
vascular malformations and vasculitis. 
Future therapeutic developments in medicine 
will include methods to manipulate angiogenesis in 
both positive and negative ways. The title of an edi- 
torial, "Two sides of the coin: stimulators for heart 
disease and inhibitors for cancer," can be modified 
to propose there may be two sides of the coin for the 
treatment ofatherosclerosis: (1) Induction of collat- 
eral vessels (arteriogenesis) to treat flow-limiting 
stenosis in cardiac and peripheral vessels and (2) 
Inhibition of plaque neovascularization associated 
with the chronic inflammatory process ofatheroscle- 
rosis to delay its progression or stabilize lesions. 
This presentation will review studies that describe 
neovascularization n human atherosclerotic lesions, 
present data that demonstrate he contribution of 
plaque neovascularization to lesion development, 
characterize biologic activities that promote plaque 
angiogenesis, and describe potential strategies for the 
applications of angiogenesis inhibitors in the treat- 
ment of vascular diseases. 
Pathologic description 
In normal vessels, the microvascular network of 
vasa vasorum is confined to the adventitital and 
outer media. In vessels with atherosclerotic involve- 
mcnt, these networks become more abundant and 
extend into the intima of lesions. Serial images taken 
during the per fusion of a silicone polymer through a
human coronary artery show a narrowed lumen at 
the site of a plaque and later filling of multiple ves- 
sels that arise from vaso vasorum. 
Putative functions of plaque neovascularization 
l. The proliferation rates of endothelial cells in 
plaque vessels vary from 0% to 43%, which indi- 
cates these vessels are found in different stages of 
development. The presence of intimal neovascu- 
larization in lesions correlates with an increased 
proliferation i dex of all cell types, and suggests 
that they are markers of growing lesions.1 
2. Intimal vessels are found in areas rich in 
macrophages, T cells, and mast cells-cell types 
that can activate angiogenesis. Their proximity to 
inflammatory infiltrates and the expression of 
adhesion molecules on the endothelium of 
plaque vessels both suggest that these vessels may 
recruit inflammatory cells into lesions and initi- 
ate a positive feedback mechanism that promotes 
inflammation i the vessel wall. 2 
3. Supply of oxygen and nutrients provided 
through plaque vessels and vaso vasorum may be
necessary precondition for growth beyond a cer- 
tain stage, after which diffusion from the artery 
lumen is insufficient o meet the metabolic 
demands of plaque tissue. 
4. Plaque vessels may be a source of intraplaque 
hemorrhage. Plaque neovascularization s more 
prevalent inculprit lesions responsible for unstable 
angina, stroke or myocardial infarction. Factors 
that stimulate plaque angiogenesis may influence 
plaque stability. 
Hypothesis 
Angiogenesis associated with atherosclerotic 
lesions is a positive regulator of plaque growth and 
inflammation. We administered potent angiogenesis 
inhibitors to apolipoprotein E-deficient mice to 
determine if such treatments reduce plaque growth. 3
Methods and results 
Intimal capillaries were first demonstrated by
immunohistochemistry aining for the endothelial 
cell markers CD31 and von Willebrand Factor 
(vWF) in advanced lesions of apoE-/- mice. 
